Related Experiment Video

Updated: May 21, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

NFATc2 is a potential therapeutic target in human melanoma

Valentina Perotti1, Paola Baldassari, Ilaria Bersani

  • 1Human Tumors Immunobiology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

The Journal of Investigative Dermatology
|June 22, 2012
PubMed

Insights

The calcineurin/nuclear factor of activated T cells c2 (NFATc2) pathway promotes melanoma cell survival. Inhibiting this pathway enhances cancer cell death, identifying NFATc2 as a potential therapeutic target for advanced melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Advanced melanoma is characterized by uncontrolled cell proliferation and resistance to apoptosis.
  • Intracellular signaling pathways play a crucial role in melanoma progression and treatment resistance.

Purpose of the Study:

  • To investigate the role of the calcineurin/nuclear factor of activated T cells c2 (NFATc2) pathway in melanoma cell survival.
  • To determine if targeting the calcineurin/NFATc2 pathway can enhance melanoma cell death and improve treatment efficacy.

Main Methods:

  • Analysis of NFATc2 expression in human melanoma cells in vitro and in vivo.
  • Treatment of melanoma cells with cyclosporin A (CsA) to inhibit the calcineurin/NFAT pathway.
  • Silencing of NFATc2 to assess its specific role in apoptosis.
  • Evaluation of apoptosis-related proteins and cell cycle inhibitors.
  • Assessment of combined effects of calcineurin/NFATc2 inhibition with standard antitumor agents (MEK/BRAF inhibitors, TNF-related apoptosis-inducing ligand).

Main Results:

  • NFATc2 expression was found to be constitutive in human melanoma.
  • CsA treatment or NFATc2 silencing led to decreased NFATc2 levels.
  • Inhibition of the calcineurin/NFAT pathway modulated cell cycle inhibitors and apoptosis-related proteins, including Apollon.
  • Targeting the calcineurin/NFATc2 pathway promoted caspase-dependent apoptosis in melanoma cells.
  • Combined inhibition of calcineurin/NFATc2 with MEK/BRAF inhibitors or TNF-related apoptosis-inducing ligand significantly increased melanoma cell death.

Conclusions:

  • The calcineurin/NFATc2 pathway exhibits an antiapoptotic role in melanoma cells.
  • NFATc2 is a key regulator of melanoma cell survival.
  • Targeting the calcineurin/NFATc2 pathway represents a promising therapeutic strategy for advanced melanoma, enhancing the efficacy of existing treatments.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...